
| G-protein, β subunit | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | G-beta | ||||||
| InterPro | IPR016346 | ||||||
| CATH | 2qns | ||||||
| SCOP2 | 2qns /SCOPe /SUPFAM | ||||||
| |||||||
| G-protein, γ subunit | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | G-gamma | ||||||
| Pfam | PF00631 | ||||||
| InterPro | IPR036284 | ||||||
| SMART | GGL | ||||||
| PROSITE | PDOC01002 | ||||||
| CATH | 2bcj | ||||||
| SCOP2 | 1gp2 /SCOPe /SUPFAM | ||||||
| OPM protein | 2bcj | ||||||
| CDD | cd00068 | ||||||
| |||||||
TheG beta-gamma complex (Gβγ) is a tightly bound dimeric protein complex, composed of one Gβ and one Gγ subunit, and is a component ofheterotrimeric G proteins. Heterotrimeric G proteins, also called guanine nucleotide-binding proteins, consist of three subunits, calledalpha, beta, andgamma subunits, or Gα, Gβ, and Gγ. When aG protein-coupled receptor (GPCR) is activated, Gα dissociates from Gβγ, allowing both subunits to perform their respective downstreamsignaling effects. One of the major functions of Gβγ is the inhibition of the Gα subunit.[1]
The individual subunits of the G protein complex were first identified in 1980 when the regulatory component ofadenylate cyclase was successfully purified, yielding threepolypeptides of different molecular weights.[2] Initially, it was thought that Gα, the largest subunit, was the major effector regulatory subunit, and that Gβγ was largely responsible for inactivating the Gα subunit and enhancing membrane binding.[1] However, downstream signalling effects of Gβγ were later discovered when the purified Gβγ complex was found to activate a cardiac muscarinicK+ channel.[3] Shortly after, the Gβγ complex associated with a mating factor receptor-coupled G protein in yeast was found to initiate apheromone response.[4] Although these hypotheses were initially controversial, Gβγ has since been shown to directly regulate as many different protein targets as the Gα subunit.[1]
Recently, possible roles of the Gβγ complex in retinalrod photoreceptors have been investigated, with some evidence for the maintenance of Gα inactivation. However, these conclusions were drawn fromin vitro experiments under unphysiological conditions, and the physiological role of the Gβγ complex in vision is still unclear. Nevertheless, recentin vivo findings demonstrate the necessity of thetransducin Gβγ complex in the functioning of rod photoreceptors under low light conditions.[5]
The Gβγ subunit is a dimer composed of two polypeptides, however it acts functionally as a monomer, as the individual subunits do not separate, and have not been found to function independently.[6]
The Gβ subunit is a member of theβ-propeller family of proteins, which typically possess four to eight antiparallel β-sheets arranged in the shape of a propeller.[7] Gβ contains a seven-bladed β-propeller, each blade arranged around a central axis and composed of four antiparallelβ-sheets.[7] The amino acid sequence contains sevenWD repeat motifs of about 40 amino acids, each highly conserved and possessing the Trp-Asp dipeptide that gives the repeat its name.
The Gγ subunit is considerably smaller than Gβ, and is unstable on its own, requiring interaction with Gβ to fold, explaining the close association of the dimer. In the Gβγ dimer, the Gγ subunit wraps around the outside of Gβ, interacting through hydrophobic associations, and exhibits no tertiary interactions with itself. The N terminushelical domains of the two subunits form acoiled coil with one another that typically extends away from the core of the dimer.[7] To date, five β-subunit and eleven γ-subunit genes have been identified in mammals.[6] The Gβ genes have very similar sequences, while significantly greater variation is seen in the Gγ genes, indicating that the functional specificity of the Gβγ dimer may be dependent on the type of Gγ subunit involved.[6]Of additional structural interest is the discovery of a so-called “hotspot” present on the surface of the Gβγ dimer; a specific site of the protein that binds to diverse range of peptides and is thought to be a contributing factor in the ability of Gβγ to interact with a wide variety of effectors.[8][9]
Synthesis of the subunits occurs in thecytosol. Folding of the β-subunit is thought to be aided by thechaperone CCT (chaperonin containing tailless-complex polypeptide 1), which also prevents aggregation of folded subunits.[10] A second chaperone, PhLP (phosducin-like protein), binds to the CCT/Gβ complex, and is phosphorylated, allowing CCT to dissociate and Gγ to bind. Finally, PhLP is released, exposing the binding site for Gα, allowing for formation of the final trimer at theendoplasmic reticulum, where it is targeted to theplasma membrane.[11] Gγ subunits are known to beprenylated (covalently modified by the addition of lipid moieties) prior to addition to Gβ, which itself has not been found to be modified. This prenylation is thought to be involved in directing the interaction of the subunit both with membrane lipids and other proteins.[12]
The Gβγ complex is an essential element in the GPCR signaling cascade. It has two main states for which it performs different functions. When Gβγ is interacting with Gα it functions as a negative regulator. In the heterotrimer form, the Gβγ dimer increases the affinity of Gα forGDP, which causes the G protein to be in an inactive state.[13] For the Gα subunit to become active, the nucleotide exchange must be induced by the GPCR. Studies have shown that it is the Gβγ dimer that demonstrates specificity for the appropriate receptor and that the Gγ subunit actually enhances the interaction of the Gα subunit with the GPCR.[14][15] The GPCR is activated by an extracellularligand and subsequently activates the G protein heterotrimer by causing aconformational change in the Gα subunit. This causes the replacement of GDP with GTP as well as the physical dissociation of the Gα and the Gβγ complex.[16]
| Effector | Signalling effect |
|---|---|
| GIRK2 | activation |
| GIRK4 | activation |
| N-type calcium channel | inhibition |
| P/Q-type calcium channels | inhibition |
| Phospholipase A | activation |
| PLCβ1 | activation |
| PLCβ2 | activation |
| PLCβ3 | activation |
| Adenylyl cyclase Type I, III, V, VI, VII | inhibition |
| Adenylyl cyclase Type II, IV | activation |
| PI3K | inhibition |
| βARK1 | activation |
| βARK2 | activation |
| Raf-1 | activation |
| Ras exchange factor | activation |
| Bruton's tyrosine kinase | activation |
| Tsk tyrosine kinase | activation |
| ARF | activation |
| Plasma membrane Ca2+ pump | activation |
| p21-activated protein kinase | inhibition |
| SNAP25 | inhibition |
| P-Rex1 Rac GEF | activation |
Once separated, both Gα and Gβγ are free to participate in their own distinct signaling pathways. Gβγ does not go through any conformational changes when it dissociates from Gα and it acts as a signaling molecule as a dimer.[17] The Gβγ dimer has been found to interact with many different effector molecules byprotein-protein interactions. Different combinations of the Gβ and Gγ subtypes can influence differenteffectors and work exclusively or synergistically with the Gα subunit.[1]
Gβγ signaling is diverse, inhibiting or activating many downstream events depending on its interaction with different effectors. Researchers have discovered that Gβγ regulatesion channels, such asG protein-gated inward rectifier channels,[3] as well ascalcium channels.[18][9] In humanPBMC, Gβγ complex has been shown to activate phosphorylation ofERK1/2.[19] Another example of Gβγ signaling is its effect of activating or inhibiting adenylyl cyclase leading to the intracellular increase or decrease of the secondary messengercyclic AMP.[20] For more examples of Gβγ signaling see table. However, the full extent of Gβγ signaling has not yet been discovered.
The Gβγ subunit plays a variety of roles in cell signalling processes and as such researchers are now examining its potential as a therapeutic drug target for the treatment of many medical conditions. However, it is recognized that there are a number of considerations to keep in mind when designing a drug which targets the Gβγ subunit:
Research has been conducted on how altering the actions of Gβγ subunits could be beneficial for the treatment of certain medical conditions. Gβγ signalling has been examined for its role in a variety of conditions includingheart failure,inflammation andleukemia.[17][21]
Heart failure can be characterized by a loss ofβ adrenergic receptor (βAR) signalling in heart cells.[22] When the βAR is stimulated bycatecholamines such asadrenaline andnoradrenaline, there is normally an increase in the contractility of the heart. However, in heart failure there are sustained and elevated levels of catecholamines which result in chronicdesensitization of the βAR receptor. This leads to a decrease in the strength of heart contractions. Some research suggests that this chronic desensitization is due to the over activation of a kinase,G protein-coupled receptor kinase 2 (GRK2), which phosphorylates and deactivates certain G protein coupled receptors .[23] When the G protein coupled receptor is activated, the Gβγ subunit recruits GRK2 which then phosphorylates and desensitizes GPCRs like the βAR.[24] Preventing the interaction of the βγ subunit with GRK2 has therefore been studied as a potential target for increasing heart contractile function. The developed molecule GRK2ct is a protein inhibitor which inhibits the signalling properties of Gβγ subunit but does not interfere with alpha subunit signalling.[25] The over expression of GRK2ct has been shown to significantly rescue cardiac function inmurine models of heart failure by blocking Gβγ subunit signalling.[26] In another study, biopsies were taken from patients with heart failure andvirally induced overexpression of GRK2ct in the heartmyocytes. Other tests showed an improvement in cardiac cell contractile function by inhibiting Gβγ.[27]
When particular GPCRs are activated by their specificchemokines Gβγ directly activatesPI3Kγ which is involved in the recruitment ofneutrophils that contribute to inflammation.[28][29][30][31] It has been discovered that the inhibition of PI3Kγ significantly reduces inflammation.[28][29] PI3Kγ is the intended target molecule in the prevention of inflammation as it is the common signalling effector of many different chemokine and receptor types involved in promoting inflammation.[30][31] Although PI3Kγ is the intended target there are otherisoforms ofPI3 which perform different functions from PI3Kγ. Since PI3Kγ is specifically regulated by Gβγ, while other isoforms of PI3 are largely regulated by other molecules, inhibiting Gβγ signalling would provide the desired specificity of a therapeutic agent designed to treat inflammation.[17]
The Gβγ subunit has been shown to activate aRho guanine nucleotide exchange factor (RhoGef) genePLEKHG2 which isupregulated in a number of leukemia cell lines and mouse models of leukemia.[32]Lymphocytechemotaxis as a result ofRac andCDC42 activation as well asactinpolymerization is believed to be regulated by the Gβγ activated RhoGef. Therefore, a drug inhibiting the Gβγ could play a role in the treatment of leukemia.[21]